A practical reference on Gastric protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Knowledge Training and experience Reagents and materials preparation Characteristics of operational steps Calibration, quality control, and proficiency testing materials Test system troubleshooting and equipment maintenance Interpretation and judgment The Centers for Medicare & Medicaid Services (CMS) has the primary responsibility for the operation of the CLIA Program. Within CMS, the program is implemented by the Center for Medicaid and State Operations, Survey and Certification Group, and the Division of Laboratory Services. List of CLIA test complexity categorizations:
== Alternative Medical Causes of Altered Turgor == Altered skin turgor can be caused by chronic medical conditions completely unrelated to an individual's immediate hydration status. Systemic sclerosis, or scleroderma, is an autoimmune disorder that triggers excessive collage production, resulting in abnormally tight, hard, and shiny skin that exhibits high turgor and cannot be pinched at all. On the other hand, genetic connective tissue disorders can drastically lower baseline skin tension, making the skin hyper-elastic. Additionally, localized fluid retention or severe edema stretches the dermis tightly, masking underlying systemic dehydration by artificially inflating skin turgor measurements.
The first-generation Molteno and other nonvalved implants sometimes require the ligation of the tube until the bleb formed is mildly fibrosed and water-tight. This is done to reduce postoperative hypotony—sudden drops in postoperative intraocular pressure. Valved implants, such as the Ahmed glaucoma valve, attempt to control postoperative hypotony by using a mechanical valve. Ab interno implants, such as the Xen Gel Stent, are transscleral implants by an ab interno procedure to channel aqueous humor into the non-dissected Tenon's space, creating a subconjunctival drainage area similar to a bleb. The implants are transscleral and different from other ab interno implants that do not create a transscleral drainage, such as iStent, CyPass, or Hydrus. The ongoing scarring over the conjunctival dissipation segment of the shunt may become too thick for the aqueous humor to filter through. This may require preventive measures using antifibrotic medications, such as 5-fluorouracil or mitomycin-C (during the procedure), or other nonantifibrotic medication methods, such as collagen matrix implant, or biodegradable spacer, or later on create a necessity for revision surgery with the sole or combinative use of donor patch grafts or collagen matrix implant.
Sources: en.wikipedia.org
==== Keratan sulfate ==== Keratan sulfates have a variable sulfate content and, unlike many other GAGs, do not contain uronic acid. They are present in the cornea, cartilage, bones, and the horns of animals.
Naturally occurring dysprosium (66Dy) is composed of 7 stable isotopes, 156Dy, 158Dy, 160Dy, 161Dy, 162Dy, 163Dy and 164Dy, with 164Dy being the most abundant (28.26% natural abundance). Twenty-nine radioisotopes have been characterized, with the most stable being 154Dy with a half-life of 1.4 million years, 159Dy with a half-life of 144.4 days, and 166Dy with a half-life of 81.6 hours. All of the remaining radioactive isotopes have half-lives that are less than 10 hours, and the majority of these have half-lives that are less than 30 seconds. This element also has 12 meta states, with the most stable being 165mDy (half-life 1.257 minutes), 147mDy (half-life 55.7 seconds) and 145mDy (half-life 13.6 seconds). The primary decay mode before the most abundant stable isotope, 164Dy, is electron capture to isotopes of terbium, and after beta decay to those of holmium. Dysprosium is the heaviest element to have isotopes that are theoretically stable (163, 164), rather than only ones that are observationally stable and predicted to be radioactive. 164Dy has a surprisingly large thermal neutron absorption and the product isotope 165Dy has found medical use (see below).
Iranian officials described the attack as an attempt to derail diplomacy, noting that Kharazi was overseeing a possible meeting between Iranian officials and US vice president JD Vance. Airstrikes on the strategically important Hengam Island in the Strait of Hormuz caused seven injuries. Netanyahu asserted that the US–Israeli strikes have eliminated Iran's ability to produce nuclear weapons and ballistic missiles, thereby removing "two existential threats" to Israel. Late in the day on 1 April, Trump made a speech addressing the nation, in which he said that the strikes have "dramatically curtailed" Iranian missile and drone systems, and added that the attacks on Iran will escalate over the next two to three weeks to "bring them back to the Stone Ages, where they belong". On 2 April, two US strikes on the B1 bridge between Tehran and Karaj, which was described as the highest bridge in the Middle East, reportedly killed eight people and wounded 95 others, causing it to collapse. Experts assessed the attack as a possible war crime; it was celebrated by Trump. At the time of the attack, many Iranian families had been gathered in the parks below the bridge to celebrate Sizdah Be-dar. Iran revealed major damage to the century-old medical center Pasteur Institute of Iran. US defense secretary Hegseth boasted of "death and destruction from the sky all day long". The IDF also announced that one of its strikes in the Kermanshah area of Iran killed Iranian ballistics missile chief Makram Atimi and several battalion commanders from Atimi's central Iranian ballistic missile unit.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.